| [1] Dent R, Trudeau M, Pritchard K I, et al. Triple-negative breast cancer: clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007,13(15 Pt 1):4429-4434.[2] Brewster A M, Chavez-MacGregor M, Brown P. Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry[J]. Lancet Oncol, 2014,15(13):e625-e634.[3] 袁中玉,王树森,朱美琴,等.不同分子亚型乳腺癌的临床特征和预后[J].中华肿瘤杂志,2008,30(6):456-461.[4] Millikan R C, Newman B, Tse C K, et al. Epidemiology of basal-like breast cancer[J]. Breast Cancer Res Treat, 2008,109(1):123-139.[5] Yuan Z Y, Wang S S, Gao Y, et al. Clinical characteristics and prognosisof triple-negative breast cancer: a report of 305 cases[J]. Ai Zheng, 2008,27(6):561-565.[6] 洪雷,魏素菊,马静,等.501例三阴乳腺癌患者预后生存因素分析[J].中国卫生统计,2015,32(1):66-67.[7] Hernandez-Aya L F, Chavez-MacGregor M, Lei X, et al. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer[J]. J Clin Oncol, 2011,29(19):2628-2634.[8] Rakha E A, EI-Sayed M E, Green A R, et al. Prognostic marker in triple-negative breast cancer[J]. Cancer, 2007,109(1):25-32.[9] Mrklic I, Pogoreli Z, Capkun V, et al. Expression of androgen receptors in triple negative breast carcinomas[J]. Acta Histochem, 2013,115(4):344-348.[10] Heitz F, Harter P, Lueck H J, et al. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases[J]. Eur J Cancer, 2009,45(16):2792-2798.[11] Zhang L, Hao C, Dong G, et al. Analysis of Clinical Features and Outcom of 356 Triple-Negative Breast Cancer Patients in China[J]. Breast Care(Basel), 2012,7(1):13-17.[12] 张丽,赵晓辉,佟仲生,等.356例三阴性乳腺癌的临床特征及预后多因素分析[J].中国肿瘤临床,2010,37(18):1045-1049.[13] 张毅,王燕,李玉军,等.三阴性乳腺癌的临床病理学特点及其预后影响因素[J/CD].中华普通外科学文献:电子版,2010,4(4):336-340.[14] 王宝娜,王翔,王靖,等.三阴性乳腺癌578例临床病理特点及预后分析[J/CD].中华临床医师杂志:电子版,2012,6(1):26-29.[15] Perou C M, Sorlie T, Eisen M B, et al. Molecular portraits of human breast tumours[J]. Nature, 2000,406(6797):747-752.[16] Banerjee S, Reis-Filho J S, Ashley S, et al. Basal-like breast carcinomas: clinical outcome and response to chemotherapy[J]. J Clin Pathol, 2006,59(7):729-735.[17] Nielsen T O, Hsu F D, Jensen K, et al. Immunohistochenical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J]. Clin Cancer Res, 2004,10(16):5367-5374.[18] Wang Z C, Lin M, Wei L J, et al. Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancer[J]. Cancer Res, 2004,64(1):64-71.[19] Fasano J, Muggia F. Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development[J]. Ann Oncol, 2009,20(4):609-614.[20] Foulkes W D, Stefansson I M, Chappuis P O, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer[J]. J Natl Cancer Inst, 2003,95(19):1482-1485.[21] 陈曲,哈敏文,包翠芬.BRCA-1在三阴性乳腺癌中的表达及意义[J].数理医药学杂志,2012,25(5):513-515.[22] Lakhani S R, Reis-Filho J S, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype[J]. Clin Cancer Res, 2005,11(14):5175-5180.[23] Livacy C A, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma[J]. Mod Pathol, 2006,19(2):264-271.[24] Thompson A M, Lane D P. P53 transcriptional pathways in breast cancer: the good, the bad and the complex[J]. J Pathol, 2010,220(4):401-403.[25] Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients[J]. Breast Cancer Res, 2006,8(4):R34.[26] 何奇,王杰,邵玉国,等.三阴性乳腺癌的临床病理特征与预后分析[J].中华医学杂志,2009,89(4):243-247.[27] 张勤,刘红.p53 在三阴性乳腺癌中的表达及临床意义[J].中国肿瘤临床,2011,38(4):214-217.[28] Linderholm B K, Hellborg H, Johansson U, et al. Significantly higher levels of vascular endothelial growth factor(VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer[J]. Ann Onc, 2009,20(10):1639-1646.[29] Riaz M, van Jaarsveld M T, Hollestelle A, et al. miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific mirnas[J]. Breast Cancer Res, 2013,15(2):R33.[30] Cascione L, Gasparini P, Lovat F, et al. Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer[J]. PLoS One, 2013,8(2):e55910.[31] Hu J, Xu J, Wu Y, et al. Identification of microRNA-93 as functional dysregulated miRNA in triple-negative breast cancer[J]. Tumour Biol, 2015,36(1):251-258.[32] Black D M, Hunt K K, Mittendorf E A. Long term outcomes reporting the safety of breast conserving therapy compared to mastectomy: 20-year results of EORTC 10801[J]. Gland Surg, 2013,2(3):120-123.[33] Steward L T, Gao F, Taylor M A, et al. Impact of radiation therapy on survival in patients with triple-negative breast cancer[J]. Oncol Lett, 2014,7(2):548-552.[34] Caudle A S, Yu T K, Tucker S L, et al. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy[J]. Breast Cancer Res, 2012,14(3):R83.[35] 周波,谢菲,王思源,等.紫杉类联合蒽环类的新辅助化疗方案治疗三阴乳腺癌的疗效及预后[J].中国癌症杂志,2009,19(2):129-132.[36] Sikov W M, Berry D A, Perou C M, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage Ⅱ to Ⅲ triple-negative breast cancer: CALGB 40603(Alliance)[J]. J Clin Oncol, 2015,33(1):13-21.[37] Gluz O, Nitz U A, Harbeck N, et al. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial[J]. Ann Oncol, 2008,19(5):861-870.[38] Golshan M, Garber J E, Gelman R, et al. Does neoadjuvant bevacizumab increase surgical complications in breast surgery?[J]. Ann Surg Oncol, 2011,18(3):733-737. |
